Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
Turnstone Bio Goes IPO to Fund Clinical Tests of New Kind of Cancer Cell Therapy
